Viagra Tablet, Film Coated
Product Images NDC 58151-427

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Viagra (NDC 58151-427). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Viatris Specialty Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Sildenafil Citrate Structural Formula (Image 01)

Chemical structure of sildenafil citrate, the active ingredient in Viagra. The diagram shows the molecular arrangement including rings and functional groups characteristic of sildenafil citrate.*

FDA Label Image

Figure 1 (Image 02)

A line graph comparing the effect of sildenafil 100 mg and placebo on systolic blood pressure over 24 hours post dose. The y-axis shows systolic blood pressure changes in mmHg, and the x-axis represents time in hours from pre-dose to 24 hours post dose. Two lines track blood pressure variation for sildenafil and placebo groups.*

FDA Label Image

Figure 2 (Image 03)

A line graph showing the change in a parameter labeled ESP (mmHg) over time postdose (hours). Two data sets are plotted: Doxazosin + Placebo and Doxazosin + Sildenafil 25 mg, distinguished by different colored lines and markers.*

FDA Label Image

Figure 3 (Image 04)

A line graph comparing the change in systolic blood pressure (SBP) over time (hours) for two treatments: Doxazosin plus placebo and Doxazosin plus Sildenafil 50 mg. The x-axis shows time postdose in hours up to 8 hours, and the y-axis shows the change in SBP in mmHg ranging from -50 to 40.*

FDA Label Image

Figure 4 (Image 05)

A line graph showing the change in mean arterial pressure (mmHg) over time (hours) after dosing. Two lines compare the effects of Doxazosin combined with Sildenafil 100 mg versus Doxazosin combined with placebo over an 8-hour period.*

FDA Label Image

Figure 5 (Image 06)

A line graph showing plasma concentration (ng/mL) over time post dose (hours) comparing commercial and test tablets of sildenafil citrate. The graph illustrates how plasma concentration changes from 0 to 24 hours after oral administration, with peak concentration occurring within the first few hours for both tablet types.*

FDA Label Image

Figure 6 (Image 07)

Two bar charts comparing the effect of Viagra and placebo on maintenance of erection by baseline score. The vertical axis shows percentage of patients at endpoint, and the horizontal axis shows baseline scores from 0 to 5. Different bars represent varying levels of response from 0 to 5, illustrating patient outcomes under each condition.*

FDA Label Image

Figure 7 (Image 08)

Bar graph depicting the percentage of patients reporting improvement across different treatment groups for Viagra tablets. The groups include placebo, Viagra 25 mg, 50 mg, and 100 mg strengths. Percentages increase from placebo to 100 mg, illustrating a trend of higher reported improvement with higher doses.*

FDA Label Image

Viagra (sildenafil Citrate) Tablets 25 mg Bottle Label (Image 09)

Viagra 25 mg tablets (sildenafil citrate) film-coated oral tablets in a package containing 30 tablets. The label includes storage instructions, distributor information for Viatris Specialty LLC, and a barcode. The product is Rx only and manufactured by Viatris.*

FDA Label Image

Viagra (sildenafil Citrate) Tablets 50 mg Bottle Label (Image 10)

Label for Viagra (sildenafil citrate) tablets, 50 mg strength, film-coated oral tablets. The label indicates a package size of 30 tablets. It is distributed by Viatris Specialty LLC and includes storage instructions and a barcode. Marked Rx only.*

FDA Label Image

Viagra (sildenafil Citrate) Tablets 100 mg Bottle Label (Image 11)

Label for Viagra sildenafil citrate 100 mg film-coated tablets. The package contains 30 tablets for oral use. Labeler is Viatris Specialty LLC. Storage instructions specify 25°C (77°F) with permitted excursions and child-resistant container dispensing. The label includes an NDC 58151-428-93 and Viatris logo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.